Will Radiation/Chemotherapy Treatment of Cervical Cancer Work Better With Medication That May Improve Anemia?
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00039884|
Recruitment Status : Unknown
Verified June 2002 by Mirhashemi, Ramin, M.D..
Recruitment status was: Active, not recruiting
First Posted : June 17, 2002
Last Update Posted : June 24, 2005
|Condition or disease||Intervention/treatment||Phase|
|Anemia Cervix Neoplasms||Drug: NESP - Novel Erythropoiesis Stimulating Protein||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||64 participants|
|Intervention Model:||Single Group Assignment|
|Official Title:||Phase II Study of NESP (Novel Erythropoiesis Stimulating Protein) During Concurrent Chemo-Radiation for the Treatment of Cervical Carcinoma.|
|Study Start Date :||September 2001|
|Estimated Study Completion Date :||March 2003|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00039884
|United States, Florida|
|Sylvester Comprehensive Cancer Center/JMH|
|Miami, Florida, United States, 33136|